Proteogenomics is an emerging field at the intersection of genomics and proteomics. Many variant peptides corresponding to single nucleotide variations (SNVs) are associated with specific diseases. The aim of this study was to demonstrate the feasibility of proteogenomic-based variant peptide detection in disease models and clinical specimens. We sought to detect p53 single amino acid variant (SAAV) peptides in breast cancer tumor samples that have been previously subjected to sequencing analysis. Initially, two cancer cell lines having a cellular tumor antigen p53 (TP53) mutation and one wild type for TP53 were analyzed by selected reaction monitoring (SRM) assays as controls. One pool of wild type and one pool of mutated for TP53 cytosolic extracts were assayed with a shotgun proteogenomic workflow. Furthermore, 18 individual samples having a mutation in TP53 were assayed by SRM. Two mutant p53 peptides were successfully detected in two cancer cell lines as expected from their DNA sequence. Wild type p53 peptides were detected in both cytosolic pools, however, none of the mutant p53 peptides were identified. Mutations at the protein level were detected in two cytosolic extracts and whole tumor lysates from the same patients by SRM analysis. Six thousand and six hundred and twenty eight non-redundant proteins were identified in the two cytosolic pools, thus greatly improving a previously reported cytosolic proteome. In the current study we show the great potential of using proteogenomics for the direct identification of cancer-associated mutations in clinical samples and we discuss current limitations and future perspectives.

, , , ,,
Clinical Chemistry and Laboratory Medicine: Associated with FESCC and IFCC
Erasmus MC: University Medical Center Rotterdam

Dimitrakopoulos, L. (Lampros), Prassas, I. (Ioannis), Berns, E., Foekens, J., Diamandis, E.P. (Eleftherios P.), & Charames, G.S. (George S.). (2017). Variant peptide detection utilizing mass spectrometry: Laying the foundations for proteogenomic identification and validation. Clinical Chemistry and Laboratory Medicine: Associated with FESCC and IFCC, 55(9), 1291–1304. doi:10.1515/cclm-2016-0947